Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
At a glance
Conditions
NCT07393373
Where you'd take part
This study runs at 24 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Astrid Lindgren Children's Hospital
Solna, Swedenno site contact published
Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants
Toulouse, Franceno site contact published
Children's Hospital of Eastern Ontario Research Institute
Ottawa, Ontario, Canadano site contact published
Children's National Hospital
Washington D.C., District of Columbiano site contact published
Childrens Hospital Colorado
Aurora, Coloradono site contact published
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohiono site contact published
Glasgow Clinical Research Facility, Queen Elizabeth University Hospital
Glasgow, Scotland, United Kingdomno site contact published
Haukeland University Hospital
Bergen, Norwayno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- QED Therapeutics SVP, Clinical Development · STUDY_DIRECTOR · QED Therapeutics, a BridgeBio company
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence of treatment emergent adverse events (TEAE) and serious TEAE10 years
- Changes over time in standing height Z-score in relation to HCH and non-HCH growth charts10 years